Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKZF2 | Q9UKS7 | 13/20 | 0.52 |
| ▸ | KAT2B | Q92831 | 4/20 | 0.51 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.51 |
| ▸ | IKZF1 | Q13422 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30830784 | 0.95 | IKZF2 (0.59) | IKZF2KAT2BBRD9IKZF1 | |
| SCHEMBL30830526 | 0.94 | IKZF2 (0.52) | IKZF2KAT2BBRD9IKZF1 | |
| SCHEMBL30830800 | 0.93 | IKZF2 (0.52) | IKZF2KAT2BBRD9IKZF1 | |
| SCHEMBL30830574 | 0.92 | IKZF2 (0.49) | IKZF2KAT2BBRD9IKZF1 | |
| SCHEMBL30830754 | 0.89 | IKZF2 (0.47) | IKZF2KAT2BBRD9IKZF1 | |
| SCHEMBL30830820 | 0.89 | IKZF2 (0.61) | IKZF2IKZF1 | |
| SCHEMBL30830885 | 0.89 | KAT2B (0.55) | KAT2BBRD9 | |
| SCHEMBL30830701 | 0.89 | IKZF2 (0.59) | IKZF2IKZF1 | |
| SCHEMBL30830749 | 0.89 | IKZF2 (0.55) | IKZF2KAT2BBRD9IKZF1 | |
| SCHEMBL30830607 | 0.89 | IKZF2 (0.59) | IKZF2KAT2BBRD9IKZF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4581025-A1 | PYRIDAZINON DERIVATIVES AS KAT2 DEGRADERS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | Auron Therapeutics, Inc. (US) | 2025-07-09 | — | — | EP | disclosed |
| WO-2024050078-A1 | PYRIDAZINON DERIVATIVES AS KAT2 DEGRADERS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | AURON THERAPEUTICS, INC. (US) | 2024-03-07 | — | — | WO | disclosed |